moneyheap
BEAM · Analysis updated Nov 10, 2026, 6:00 PM ET
Why is Beam Therapeutics Inc. Common Stock (BEAM) stock moving?
Beam reported positive topline pivotal data from the BEACON trial of risto-cel in sickle cell disease on Nov 10, meeting the primary endpoint at interim analysis, with a BLA possible as early as year-end 2026. The stock still closed at 25.15, down 6.9% from 27.02, after trading as low as 23.6 on 3.1M shares, well above the roughly 1.3M to 2.0M of recent sessions. The sell-off suggests the market treated the data as expected or discounted the interim nature of the readout. Q3 results on Nov 3 missed: EPS of $(1.28) versus $(1.15) expected and sales of $307K versus $8.75M expected, though Beam ended the quarter with $1.0B in cash and runway into mid-2029. Analyst price targets range from $30 (Wedbush) to $78 (Canaccord), with Guggenheim at $51 and JonesTrading at $35, and all cited firms rate the stock Buy or Outperform. Completion of BEAM-302 pivotal dosing in 1H 2027 and BEAM-304 dosing in early 2027 add longer-dated catalysts. Over the last 30 days the stock has traded between 23.2 and 29.8, and the Oct 28 spike to 28.78 on 5.0M shares is not explained by the supplied news.
News behind the analysis
- Beam Therapeutics Announces Positive Topline Pivotal Data from BEACON Phase 1/2 Trial of Risto-celBeam reported positive topline results from the Phase 1/2 BEACON study of risto-cel in sickle cell disease. The release is the key clinical update in the window.
- Beam Therapeutics Says Risto-Cel Met Primary Endpoint At Interim Analysis Of Single-Arm Phase 1/2 BEACON Trial In Sickle Cell Disease; Plans BLA As Early As Year-End 2026The interim analysis of the single-arm trial met the primary endpoint, and Beam plans a BLA submission as early as year-end 2026.
- Guggenheim Maintains Buy on Beam Therapeutics, Lowers Price Target to $51Guggenheim kept its Buy rating and cut its price target from $55 to $51.
- JonesTrading Initiates Coverage on Beam Therapeutics with Buy RatingJonesTrading initiated coverage with a Buy rating and a $35 price target.
- Canaccord Genuity Maintains Buy on Beam Therapeutics, Lowers Price Target to $78Canaccord Genuity kept its Buy rating and lowered its price target to $78 from $79.
- Wedbush Maintains Outperform on Beam Therapeutics, Raises Price Target to $30Wedbush kept its Outperform rating and raised its price target to $30.
- Beam Therapeutics to Present Updated BEACON Trial Data at 68th ASH Annual MeetingBeam will present updated clinical data from the BEACON Phase 1/2 trial of risto-cel as an oral presentation at the ASH Annual Meeting.
- Beam Therapeutics Reports Third Quarter 2026 Financial ResultsBeam reported Q3 2026 results and ended the quarter with $1.0 billion in cash, with runway expected into mid-2029. The BLA for risto-cel is expected as early as year-end 2026.
- Beam Therapeutics Q3 EPS $(1.28) Misses $(1.15) Estimate, Sales $307.000K Miss $8.752M EstimateQ3 EPS of $(1.28) missed the $(1.15) estimate, and sales of $307K missed the $8.752M estimate.
About Beam Therapeutics Inc. Common Stock
Beam Therapeutics is a Cambridge, Massachusetts biotech that develops medicines using base editing, a precise type of gene editing that changes single DNA letters without cutting both strands of DNA. It has no approved products yet. Its most advanced programs are risto-cel (BEAM-101) for sickle cell disease, which could be submitted to the FDA for approval as early as year-end 2026, and BEAM-302 for alpha-1 antitrypsin deficiency, which is now in a pivotal trial.
How it makes money
Beam does not sell any products yet, so it makes almost no money from sales. Its revenue comes mostly from collaboration and licensing deals with larger drug companies, such as an earlier partnership with Pfizer. These payments are irregular. The company runs at a loss and pays for its research mainly with cash raised from investors, holding about $1.2 billion in cash and investments as of mid-2026. Its long-term goal is to earn money by selling approved therapies, starting with risto-cel.
What usually moves BEAM
- Clinical trial data for BEAM-302 and risto-cel
- FDA filing and approval decisions
- Cash burn and the risk of selling new shares to raise money
- Gene-editing sector sentiment and competing approvals
- Partnership or licensing deals